Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

May 16, 2018

In re Novartis and Par Antitrust Litigation

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. July 26, 2023

    Novartis Direct Buyers' Attys Get $42M In Drug Delay Case

    A New York federal judge awarded counsel for direct purchasers of Novartis' hypertension medication $42.15 million in attorney fees, according to an order Tuesday granting final approval of a $126 million settlement resolving claims that Novartis had an illicit arrangement with Par Pharmaceuticals to delay the release of an Exforge generic.

7 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login